中国临床药学杂志

目的分析日间化疗中心患者使用聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)的现状,为该药的管理提供参考数据。方法收集日间化疗中心在2019年5-7月使用PEG-rhG-CSF患者的病历资料,结合国内外指南及专家共识进行用药分析。结果日间化疗中心共254人340例次使用PEG-rhG-CSF,其中预防性使用305例次(89.71%),治疗性使用35例次(10.29%),均通过皮下注射给药,用药剂量分别为6 mg(84.41%)和3 mg(15.59%),剂量范围分别为69.36～166.2μg·kg^-1和34.09～83.33μg·kg^-1。预防性用药中,距上一程放化疗间隔符合指南标准的仅占27.87%。PEG-rhG-CSF距下一程放化疗<12 d及2次PEG-rhGCSF间隔<7 d分别占6.18%和1.29%。不良反应有白细胞增多、发热、疲乏和失眠。结论 PEG-rhG-CSF在日间化疗中心以预防性使用为主,并存在一定的不合理现象,应重点关注距上一程放化疗间隔的问题。

AIM To analyze the current situation of pegylated recombinant human granulocyte colonystimulating factor(PEG-rhG-CSF) for patients in the day-time chemotherapy center and provide reference data for the management of this drug. METHODS The medical records of patients,who used PEG-rhG-CSF in the day-time chemotherapy center from May to July 2019, were collected and analyzed based on domestic and foreign guidelines and expert consensus. RESULTS PEG-rhG-CSF was administrated subcutaneously in 254 patients for 340 times in the daytime chemotherapy center, among them 305 times(89.71%) for prophylactic use and 35 times(10.29%) for therapeutic use with the dosage of 6 mg(84.41%) and 3 mg(15.59%), and the dosage range was 69.36-166.2 μg·kg^-1 and 34.09-83.33 μg·kg^-1 respectively. Only 27.87% of the patients met the guidelines for the intervals from the previous course of chemoradiotherapy. The time intervals < 12 d and < 7 d were 6.18% and 1.29% respectively. Adverse reactions included leukocytosis, fever, fatigue, and insomnia. CONCLUSION PEG-rhG-CSF is mainly used for prophylaxis in the day-time chemotherapy center, and there is some unreasonable phenomena in use. Attention should be paid to the interval from the previous course of chemoradiotherapy.